​Clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR‐associated 9 (Cas‐9) technology holds tremendous potential as a gene editing tool. Different strategies have been adopted for in vitro and in vivo delivery of CRISPR/Cas9, including both viral and non‐viral. The possibility of tailoring properties of nanosized systems makes the molecular design of self‐assembled non‐viral delivery systems based on organic (lipids and polymers) and hybrid (zeolitic imidazolate frameworks, ZIF and gold nanoparticles) materials of a great interest in CRISPR/Cas9 delivery. This review highlights the progress and challenges of organic and hybrid CRISPR/Cas9 delivery vehicles.